DNA Biomed Solns (DNA) — Cash Flow Quality Index
DNA Biomed Solns (DNA) has a Cash Flow Quality Index of -0.21x as of June 2023. Operating cash flow of ILA-265.00K is below net income of ILA1.27 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore DNA Biomed Solns long-term investment allocation to see how much of total assets are deployed in long-term investments.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
DNA Biomed Solns Cash Flow Quality Index (2017–2024)
Historical Cash Flow Quality Index for DNA Biomed Solns across 3 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check DNA Biomed Solns tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Annual Cash Flow Quality Index for DNA Biomed Solns (2017–2024)
Year-by-year earnings quality comparison for DNA Biomed Solns. For live market cap and the full company financial profile, see DNA Biomed Solns (DNA) market capitalisation.
| Year | Quality Index | Operating CF (ILA) | Net Income | YoY Change |
|---|---|---|---|---|
| 2024 | 0.07x | ILA1.61 Million | ILA22.10 Million | ▲ +157.4% |
| 2021 | -0.13x | ILA-2.33 Million | ILA18.37 Million | ▼ -881.3% |
| 2017 | -0.01x | ILA-1.91 Million | ILA147.36 Million | — |